These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1216 related articles for article (PubMed ID: 8313379)

  • 1. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
    Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
    Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
    Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of EJ cells tumorigenicity.
    Tone T; Kashani-Sabet M; Funato T; Shitara T; Yoshida E; Kashfian BI; Horng M; Fodstadt O; Scanlon KJ
    In Vivo; 1993; 7(6A):471-6. PubMed ID: 8193263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer.
    Li M; Lonial H; Citarella R; Lindh D; Colina L; Kramer R
    Cancer Gene Ther; 1996; 3(4):221-9. PubMed ID: 8853546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme.
    Funato T; Shitara T; Tone T; Jiao L; Kashani-Sabet M; Scanlon KJ
    Biochem Pharmacol; 1994 Oct; 48(7):1471-5. PubMed ID: 7945447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
    Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
    Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
    Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
    Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
    Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
    Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive overexpression of a 89 kDa heat shock protein gene in the HBL100 human mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene.
    Lebeau J; Le Chalony C; Prosperi MT; Goubin G
    Oncogene; 1991 Jul; 6(7):1125-32. PubMed ID: 1861862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line.
    Eastham JA; Ahlering TE
    J Urol; 1996 Sep; 156(3):1186-8. PubMed ID: 8709343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ribozyme targeted the point-mutation of activated oncogene inhibits its expression in vivo].
    Liu G; Chen Y; Zhao X; Dong Y; Chen D
    Yi Chuan Xue Bao; 1996; 23(6):477-85. PubMed ID: 9084224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the Ha-ras (RasH) oncogene in mediating progression of the tumor cell phenotype (review).
    Boylan JF; Jackson J; Steiner MR; Shih TY; Duigou GJ; Roszman T; Fisher PB; Zimmer SG
    Anticancer Res; 1990; 10(3):717-24. PubMed ID: 2195986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
    Su ZZ; Austin VN; Zimmer SG; Fisher PB
    Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation.
    Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K
    Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme.
    Bi F; Fan D; Hui H; Wang C; Zhang X
    Cancer Gene Ther; 2001 Nov; 8(11):835-42. PubMed ID: 11773973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of the neoplastic phenotype of EBV-established B lymphocytes by the human Ha-ras oncogene.
    Nasi S; Sirinian MI; Panetta G; Marchetti A; Jucker R
    Oncogene; 1990 Jan; 5(1):117-22. PubMed ID: 2157177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibited neoplastic phenotype by the c-Ha-ras antisense RNA.
    Lu GR; Wu CJ; Ke Y; Xiong X; Li YJ; Liu JM; Xu Y; Xu W; Li JY; Deng GR
    Sci China B; 1991 Dec; 34(12):1485-91. PubMed ID: 1801843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo.
    Kröger A; Dallügge A; Kirchhoff S; Hauser H
    Oncogene; 2003 Feb; 22(7):1045-56. PubMed ID: 12592391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs.
    Fan H; Villegas C; Huang A; Wright JA
    Cancer Res; 1996 Oct; 56(19):4366-9. PubMed ID: 8813126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ha-Ras-1 oncogene dosage differentially affects Balb/3T3 cells' growth factor requirement and tumorigenicity.
    Kovary K; Armelin MC; Armelin HA
    Oncogene Res; 1989; 4(1):55-64. PubMed ID: 2654813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.